Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab with PDT for Neovascular AMD
NCT00813891Phase 4Unknown
- Sponsor
- McGill University Health Centre
- Start
- Jan 2009
- Primary completion
- Dec 2009
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised trial of ranibizumab in neovascular age-related macular degeneration (NVAMD) (3 arms), sponsored by McGill University Health Centre. Primary endpoint: Mean change from baseline in Best Corrected Visual Acuity at 6 months. Status: unknown.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00813891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00813891.